All articles tagged with #grail
Results from the UK's largest randomized trial of the Galleri multi-cancer blood test showed no statistically significant reduction in late-stage cancers (stages 3–4) when added to standard screening; while a secondary look at stage-4 cancers suggested a 14% reduction, mortality outcomes are still pending.
A 13th–14th century illuminated manuscript known as the Clermont-Tonnerre Grail—one of the earliest texts of the Arthurian legend featuring Merlin—has been in private hands for about 700 years and is headed to Christie’s in London for a July sale, with an estimated price of up to $2.7 million (£1.5–2 million). The vellum work, dating circa 1290–1310, contains Old French text from the Lancelot-Grail cycle and 126 gold-leaf illustrations; it has never been publicly exhibited or extensively studied, and its provenance traces through a long private collection.
A first-person look at Grail’s Galleri multi-cancer early detection blood test: the $824 home draw returned no cancer signal, but real-world results are mixed and medical groups remain cautious, with limited evidence of mortality benefit and concerns about false positives and missed cancers. While some see potential, experts emphasize that MRI scans or traditional symptom-driven screening remain more established, and readers are advised to discuss symptoms with a doctor and not rely on MCED tests as a sole screening tool.
Grail's stock fell more than 45% after-hours after NHS-Galleri trial failed to meet its primary endpoint, showing no statistically significant reduction in later-stage cancers overall; however, a pre-specified group of 12 deadly cancers showed a favorable trend toward fewer stage III-IV cancers, with greater reductions in stage IV diagnoses across sequential screening rounds. The company will extend follow-up by 6-12 months to seek stronger effects, and it also reported 17% full-year revenue growth to $147.2 million, with U.S. Galleri revenue up 26% to $136.8 million.
In a large UK trial of 142,000 adults over three years, Grail's Galleri multi-cancer blood test did not reduce late-stage cancers (stages 3–4), though researchers noted a secondary signal of fewer Stage 4 cancers; the test remains FDA-unapproved, is sold with limited insurer coverage, and Medicare coverage remains under legislative review.
Grail's Galleri blood test for early cancer detection failed to meet its primary endpoint in a large NHS-backed study, renewing questions about its clinical utility despite some detected benefits. Grail reported selling 185,000 tests in 2025 for $136.8 million, and its stock fell about 47% after hours following the setback.
The article discusses the Galleri multi-cancer early detection blood test, which studies DNA fragments to detect 50 types of cancer, highlighting its potential, limitations, and the author's personal experience with a negative result, emphasizing that it is not a replacement for existing screenings but a promising supplement.
A blood test called Galleri, capable of detecting 50 types of cancer with nearly 50% accuracy, is being tested on NHS patients and shows promise for annual screening of over-50s to catch cancer early, potentially saving many lives and improving survival rates.
WHO scientists are questioning the clinical trial endpoint being used by Grail to evaluate its Galleri blood test, which aims to detect multiple types of tumors early. The test is currently available in the U.S. but not yet approved by the FDA or reimbursed by Medicare, and Grail generated $30 million in revenue in the fourth quarter of 2023 while incurring a $197 million loss. If successful, the Galleri test could revolutionize cancer screening as a multi-cancer early detection test, but concerns about its evaluation process persist.
Grail, a company specializing in blood cancer tests, is seeking a new owner as it aims to expand its services. The company's tests have proven effective in detecting pancreatic cancer, a typically hard-to-diagnose disease. Patients like Paul Schneider, who was diagnosed with pancreatic cancer through a Grail blood test, have benefited from early detection and subsequent treatment.
Illumina, a gene sequencing company, has announced plans to divest cancer diagnostic test maker Grail after facing antitrust battles with U.S. and European regulators for over two years. The divestiture will be executed through a third-party sale or capital markets transaction, with the terms expected to be finalized by the second quarter of 2024. Grail, valued at $7.1 billion, is seeking to market a blood test that can diagnose various types of cancer. Illumina had reacquired Grail in 2021 despite competition concerns, and a U.S. appeals court recently ordered the Federal Trade Commission (FTC) to conduct a new review of the acquisition. The FTC had expressed concerns about Illumina's dominant position in DNA sequencing and its potential impact on competition. The divestment is also a response to pressure from activist investor Carl Icahn, who led a successful board challenge and sued Illumina over the Grail deal.
Illumina, the leading maker of DNA sequencing machines, has announced that it will divest Grail, the developer of a multi-cancer screening test, following a court decision that deemed their merger anti-competitive. Illumina plans to sell or list Grail on capital markets by the end of the second quarter of 2024, marking the end of a disastrous attempted merger that began in 2016 when Illumina spun out Grail to raise funds before re-acquiring it for $7.1 billion in 2020.
Gene-sequencing company Illumina has announced its decision to sell Grail, a cancer test developer that it acquired for $7.1 billion in 2021. This move comes after a federal appeals court largely upheld a Federal Trade Commission ruling that Illumina should unwind its deal with Grail on antitrust grounds. The sale of Grail will be executed through a third-party sale or a capital market transaction, with the goal of finalizing the deal by the end of the second quarter next year. This case is seen as a test of regulators' efforts to prevent big companies from acquiring fledgling innovators, and it may have implications for other tech giants and dominant companies in their respective fields.
The planned $7.1 billion acquisition of cancer test developer Grail by Illumina has been sent back to the Federal Trade Commission (FTC) by a U.S. appeals court, which upheld the regulator's finding that the deal is anticompetitive. The court determined that the FTC used a standard incompatible with the Clayton Act and vacated its order, remanding the case for reconsideration. Illumina has filed a draft registration statement for a potential divestiture of Grail, and if it fails to overturn the European Commission's order or the appeals court rules against it, Illumina will proceed with the divestiture.
A U.S. appeals court has struck down a Federal Trade Commission (FTC) order against Illumina's acquisition of cancer diagnostic test maker Grail, stating that the agency applied the wrong legal standard. The court's decision requires the FTC to reconsider the deal. While the panel acknowledged the FTC's evidence of potential competition reduction, it also noted that the agency failed to properly consider Illumina's commitment to continue selling its DNA sequencing services to other firms. Illumina had argued that the FTC unconstitutionally exercised its powers, but the court rejected this claim. The FTC sees the decision as a victory for antitrust enforcement, while Illumina is reviewing the ruling.